文献速递治疗药物监测与药物基因组学特殊人群用药

成人囊性纤维化患者中Elexacaftor、Tezacaftor和Ivacaftor的群体药代动力学

Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic Fibrosis.
PubMed 文献 · Clin Pharmacokinet · 2025-05-22

本研究基于法国国家观察性队列,纳入325名成人囊性纤维化患者,采集552份血浆浓度,构建ETI的群体药代动力学模型。结果显示三种化合物均符合一室模型,体重、年龄、胰腺外分泌功能不全和CFTR基因型是间个体变异的主要来源,提示治疗药物监测可能对特定患者有益。

要点

  • ETI在成人CF患者中呈现大幅间个体变异,AUC范围跨度大。
  • 体重、年龄、胰腺外分泌功能不全和CFTR基因型是变异的主要来源。
  • 低体重、高龄、携带一个ETI响应CFTR变异或无胰腺外分泌功能不全者可能受益于TDM。

核心结论

  • 本研究建立了首个成人CF患者ETI群体药代动力学分析,识别了解释间个体变异的关键协变量。

研究设计与样本

  • 法国国家观察性队列研究,纳入325名成人CF患者,采集552份常规血浆浓度进行群体药代动力学分析。

主要发现

  • Elexacaftor和Tezacaftor的AUC0-24h范围分别为58.7-422.9 mg·h/L和38.0-207.7 mg·h/L,Ivacaftor的AUC0-12h范围为4.9-64.9 mg·h/L。
  • 最终模型识别的主要间个体变异来源为体重、年龄、胰腺外分泌功能不全和CFTR基因型。

临床怎么用

  • 对于低体重、高龄、携带一个ETI响应CFTR变异或无胰腺外分泌功能不全的患者,尤其合并这些特征时,可考虑治疗药物监测。
  • 治疗药物监测也可能用于发生不良事件、疗效降低或管理不依从的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Elexacaftor-tezacaftor-ivacaftor (ETI), a combination of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, has become the therapeutic standard of care for most people with cystic fibrosis (pwCF). People with cystic fibrosis exhibit differences in CFTR genotypes and have important differences in phenotypic characteristics including age, body weight, pancreatic status, disease severity, and comorbidities. While these differences predict large interindividual variability (IIV) in ETI exposure, there is a unique dose regimen recommended for adults. This raises questions around the "one-dose fits all" strategy. OBJECTIVES: The aims of this study were to describe real-world population pharmacokinetics (Pop-PK) of ETI in adults with CF and identify factors associated with IIV. METHOD: As part of the ongoing French national observational cohort study the Pop-PK analysis included 552 plasma concentrations drawn routinely from 325 adults with CF. RESULTS: A one-compartment model with first order absorption and elimination best represented all three compounds, and an additional lag-time for elexacaftor PK data. Large IIV was observed in ETI, with an area under the curve (AUC0-24h for elexacaftor and tezacaftor, and AUC0-12h for ivacaftor) ranging respectively, from 58.7-422.9 mg⋅h/L; 38.0-207.7 mg⋅h/L and 4.9-64.9 mg⋅h/L. The main sources of IIV identified in the final ETI Pop-PK models were body weight, age, exocrine pancreatic insufficiency and CFTR genotype. CONCLUSION: This study established the first ETI Pop-PK analysis in adults with CF and identified several covariates that explain IIV. Therapeutic drug monitoring may be beneficial for patients with a small body weight, older ages, carrying one ETI-responsive CFTR variant or those with no exocrine pancreatic insufficiency and especially for patients who combine these characteristics. Therapeutic drug monitoring may also prove to be useful in individuals experiencing adverse events, in those with reduced effectiveness, or to help manage non-adherence issues.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Magnas P, Bouazza N, Foissac F, et al. Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic Fibrosis. Clin Pharmacokinet. 2025. PMID: 40405059. doi:10.1007/s40262-025-01516-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。